Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 87 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French MOST POPULAR NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses... March 9, 2021 Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally... November 3, 2020 Reduction Not Only in Recurrences, but Also in Mortality, Observed for... December 20, 2022 Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable... August 28, 2025 Load more HOT NEWS COVID Vaccine Basics for Cancer Patients Take a Small Step Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma GreaterGood’s Mask Donations Are Helping Wildlife Sanctuaries Continue Their Essential Work
